When you hear the phrase non-traded REIT ("NTR"), most investors basically think of Blackstone's REIT ("BREIT"). BREIT is a $69 billion behemoth that makes up approximately 70% of the NTR market. Launched in 2015 and marketed to mostly high-net-worth ("HNW") individuals, BREIT contributes a whopping 17% to Blackstone's earnings (even though it makes up approximately 7% of its $991bn of AUM).
It's popularity is not surprising, BREIT has generated 11.8% annualized net return and provided a 4.5% net yield. But Blackstone's crown jewel seems to be a victim of its own success...
NTRs invest in the largely the same types of stabilized commercial real estate properties that publicly traded REITs do. The crucial difference--as the name states--is that they are not traded on exchanges and have strict liquidity provisions that limit redemptions to 2% and 5% of net asset value ("NAV") per month and quarter, respectively. Which means they exhibit only a fraction of the volatility of public REITs, whose value tends to be driven as much, if not more, by market beta as real estate fundamentals. In 2022, REITs were down over 24%. By contrast, BREIT (Class I) was up 8.4%. Quite a bit of alpha? Or subjective marking of assets? Many investors felt the latter and saw an opportunity for a potential arbitrage--take profits by selling BREIT and invest the proceeds in beaten down public REITs.
As a consequence, BREIT has been facing massive redemption requests for the better part of three quarters. Chart A below shows monthly redemption requests and payouts by BREIT since October. There has been over $12 billion of redemption requests since 3Q22 and over $9 billion of payouts to investors. (Things were getting really desperate at one point before the University of California endowment stepped in with a $4 billion (structured) investment). However, after the first couple of months, BREIT's payout rate per month has fallen sharply and redemption requests (after pausing in December) have been steadily rising again.
No comments:
Post a Comment